欧洲乳腺癌治疗市场预测至 2030 年 - 区域分析 - 按药物治疗 [靶向药物治疗(Abemaciclib、Ado-Trastuzumab Emtansine、Palbociclib、曲妥珠单抗和其他靶向药物治疗)、激素药物治疗(选择性雌激素受体调节剂、芳香酶抑制剂、和选择性雌激素受体下调剂)、化疗和免疫治疗/生物治疗]、乳腺癌类型(激素受体、HER2+和三阴性乳腺癌)和分销渠道(医院药房、药店和零售药房、网上药房) X

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 106    |    Report Code: BMIRE00029748    |    Category: Life Sciences

Europe Breast Cancer Therapeutics Market
2022年欧洲乳腺癌治疗市场价值为84.4696亿美元,预计到2030年将达到168.3617亿美元;预计 2022 年至 2030 年复合年增长率为 9.0%。

政府和私营组织加大支持推动欧洲乳腺癌治疗市场

各国政府认识到乳腺癌治疗的重要性解决乳腺癌问题,并正在实施政策以改善获得有效治疗的机会。许多政府和私人组织增加了乳腺癌治疗研究和开发的资金,从而促进了创新药物和疗法的开发。欧盟委员会乳腺癌倡议 (ECIBC) 在各个层面提供普遍可用的基本优质护理。 ECIBC 的使命是根据最新的科学研究,为女性和医疗保健从业者提供有关筛查和护理的公正、无偏见的建议。研究投资的增加使制药公司能够探索新的治疗方案,并为乳腺癌患者开发高度针对性和有效的疗法。

世界各地的多个政府机构也在采取措施,通过实施报销政策和医疗保健计划来支付患者乳腺癌治疗的费用,以改善获得这些治疗的机会。这意味着更多的患者能够负担得起这些治疗,并能够获得乳腺癌治疗的最新进展。政府支持力度的加大也为医疗保健提供者创造了有利的市场环境。有了更多的资金和资源,医疗保健提供者就能够为患者提供更广泛的治疗选择。这改善了患者的治疗效果,并使医疗保健提供者能够在市场上保持竞争力。总体而言,政府和私人组织对乳腺癌治疗的支持不断增加,推动了创新,带来了新的和改进的治疗方法。它还改善了获得这些治疗的机会,使更多患者受益。随着制药公司和医疗保健提供商继续投资于研发活动并扩大其产品范围以满足不断增长的需求,这为欧洲乳腺癌治疗市场的增长提供了重大机遇。

欧洲乳腺癌治疗市场概述

欧洲乳腺癌治疗市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。乳腺癌是英国的一种常见癌症。根据英国国家医疗服务体系 (NHS) 的数据,大约七分之一的女性在其一生中被诊断出患有乳腺癌。每年约有 55,000 名女性被诊断患有乳腺癌。

医疗行业对用新疗法治疗乳腺癌患者的更大需求导致了研发投资的增加,从而推动了市场的增长。 Breast Cancer Now 是英国最大的专门乳腺癌研究资助机构。迄今为止,已投资30801万美元(

Europe Breast Cancer Therapeutics Strategic Insights

Strategic insights for Europe Breast Cancer Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-breast-cancer-therapeutics-market-strategic-framework.webp
Get more information on this report

Europe Breast Cancer Therapeutics Report Scope

Report Attribute Details
Market size in 2022 US$ 8,446.96 Million
Market Size by 2030 US$ 16,836.17 Million
Global CAGR (2022 - 2030) 9.0%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 药物治疗
  • 靶向药物治疗
  • 激素药物治疗
  • 化疗
  • 免疫治疗/生物治疗
By 乳腺癌类型
  • 激素受体
  • HER2+
  • 三阴性乳腺癌
By 分销渠道
  • 医院药房
  • 药店和零售药房
  • 网上药房
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • Eli Lilly and Co
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc
  • Get more information on this report

    Europe Breast Cancer Therapeutics Regional Insights

    The regional scope of Europe Breast Cancer Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-breast-cancer-therapeutics-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Breast Cancer Therapeutics Market

    1. Eli Lilly and Co
    2. Eisai Co Ltd
    3. Novartis AG
    4. AstraZeneca Plc
    5. Pfizer Inc
    6. Gilead Sciences Inc
    7. Merck & Co Inc
    8. Teva Pharmaceutical Industries Ltd
    9. Amgen Inc

    Frequently Asked Questions
    How big is the Europe Breast Cancer Therapeutics Market?

    The Europe Breast Cancer Therapeutics Market is valued at US$ 8,446.96 Million in 2022, it is projected to reach US$ 16,836.17 Million by 2030.

    What is the CAGR for Europe Breast Cancer Therapeutics Market by (2022 - 2030)?

    As per our report Europe Breast Cancer Therapeutics Market, the market size is valued at US$ 8,446.96 Million in 2022, projecting it to reach US$ 16,836.17 Million by 2030. This translates to a CAGR of approximately 9.0% during the forecast period.

    What segments are covered in this report?

    The Europe Breast Cancer Therapeutics Market report typically cover these key segments-

  • 药物治疗 (靶向药物治疗, 激素药物治疗, 化疗, 免疫治疗/生物治疗)
  • 乳腺癌类型 (激素受体, HER2+, 三阴性乳腺癌)
  • 分销渠道 (医院药房, 药店和零售药房, 网上药房)
  • What is the historic period, base year, and forecast period taken for Europe Breast Cancer Therapeutics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Breast Cancer Therapeutics Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Europe Breast Cancer Therapeutics Market?

    The Europe Breast Cancer Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Eli Lilly and Co
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc
  • Who should buy this report?

    The Europe Breast Cancer Therapeutics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Breast Cancer Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.